Jin Oh Na

Jin Oh Na

Auto-generated profile, based on publicly available information

Jin Oh Na

Division of Cardiology, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Journal of Lipid and Atherosclerosis
Verified
Journal Article
Open access
EREun-Jung Rhee
Eun-Jung Rhee
HKHyeon Chang Kim
Hyeon Chang Kim
JKJae Hyeon Kim
Jae Hyeon Kim
ELEun Young Lee
Eun Young Lee
BKByung Jin Kim
Byung Jin Kim
OAOn behalf of the Committee of Clinical Practice Guideline of Korean Society of Lipid and Atherosclerosis
On behalf of the Committee of Clinical Practice Guideline of Korean Society of Lipid and Atherosclerosis

Verified
Journal Article
Open access
PDF file
DKDong Oh Kang
Dong Oh Kang
SPSo Yeon Park
So Yeon Park
BCByoung Geol Choi
Byoung Geol Choi
JNJin Oh Na
Jin Oh Na
CCCheol Ung Choi
Cheol Ung Choi
HSHong Seog Seo
Hong Seog Seo
The impact of sarcopenia on atherosclerotic cardiovascular disease remains unclear. We aimed to investigate the prognostic impact of sarcopenia on coronary artery disease (CAD). A total of 475 patients with CAD who underwent successful percutaneous coronary intervention (PCI) and computed tomography (CT) were enrolled. The cross-sectional area of skeletal muscle at the first lumbar (L1) vertebral level was measured, and sex-specific cut-off values of L1 skeletal muscle index (L1 SMI; male <31.00 cm2/m2, female <25.00 cm2/m2) were obtained. The primary outcome was 3-year all-cause mortality and the secondary outcome was 3-year major adverse cardiovascular events (MACEs). Low L1 SMI was present in 141 (29.7%) of 475 patients. The incidence of all-cause mortality (23.7% vs. 5.9%, p < 0.001) and MACEs (39.6% vs. 11.8%, p < 0.001) was significantly higher in patients with low L1 SMI than in those with high L1 SMI. In multivariate analysis, low L1 SMI was an independent predictor of higher risk of all-cause mortality (hazard ratio (HR): 4.07; 95% confidence interval (CI): 1.95–8.45; p < 0.001) and MACEs (HR: 3.76; 95% CI: 2.27–6.23; p < 0.001). These findings remained consistent after propensity score-matched analysis with 91 patient pairs (C-statistic = 0.848). CT-diagnosed low skeletal muscle mass is a powerful predictor of adverse outcomes in patients with CAD undergoing PCI.

1 January 2022 in Korean Circulation Journal
Verified
Journal Article
Open access
PDF file
SISang Hyun IHM
Sang Hyun IHM
KKKwang-il Kim
Kwang-il Kim
KLKyung Jin Lee
Kyung Jin Lee
JWJong Won Won
Jong Won Won
JNJin Oh Na
Jin Oh Na
JSJinho Shin
Jinho Shin
Korean Circulation Journal 대한심장학회지 순환기 Ihm SH, et al. Korean Circ J. 2021 Nov;52:e10. https://doi.org/10.4070/kcj.2021.0226

Verified
Journal Article
Open access
PDF file
WJWon Young Jang
Won Young Jang
DKDong Oh Kang
Dong Oh Kang
YPYoonjee Park
Yoonjee Park
JLJieun Lee
Jieun Lee
WKWoohyeun Kim
Woohyeun Kim
EKEung Ju Kim
Eung Ju Kim
The regression equation of the American College of Sports Medicine (ACSM) was a preferred method for estimating maximal oxygen consumption (VO2max). Recently, a more precise equation from the fitness registry and the importance of exercise national database (FRIEND) for healthy people was developed. This study compared VO2max estimated by the ACSM and FRIEND equations to VO2max directly measured in coronary artery disease (CAD) patients. Overall, 293 CAD patients who participated in cardiac rehabilitation between June 2015 and December 2018 were analyzed. Directly measured VO2max values were compared to the ACSM and FRIEND equations. The directly measured VO2max was significantly different from the estimated VO2max by ACSM equation (24.16 vs. 28.7 mL/kg/min, p < 0.001), which was overestimated by 20% in men and 16% in women. However, there was no statistically significant difference between the directly measured VO2max and the estimated VO2max by the FRIEND equation. (24.16 vs. 24.15 mL/kg/min, p = 0.986). In CAD patients, the estimated VO2max from the ACSM equation was significantly higher than the directly measured VO2max. In addition, estimated cardiorespiratory fitness (CRF) by the FRIEND equation showed similar results with directly measured CRF. As a result, the FRIEND equation can predict CRF more accurately than the ACSM.

12 December 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
WJWon Young Jang
Won Young Jang
WKWoohyeun Kim
Woohyeun Kim
DKDong Oh Kang
Dong Oh Kang
YPYoonjee Park
Yoonjee Park
JLJieun Lee
Jieun Lee
EKEung Ju Kim
Eung Ju Kim
We investigated reference values for cardiorespiratory fitness (CRF) for healthy Koreans and Koreans with coronary heart disease (CHD) and used them to identify inter-ethnic differences in CRF, differences over time in CRF, and differences in CRF between the healthy population and patients with CHD. The study population for healthy Koreans was derived from the database of KISS FitS (Korea Institute of Sports Science Fitness Standards) between 2014 and 2015. The study population for Koreans with CHD was derived from the database of the Korea University Guro Hospital Cardiac Rehabilitation Registry between June 2015 and December 2018. In healthy Koreans, there was a significant difference between sex and age groups for VO2 max. The VO2 max of healthy Koreans differed from that of Westerners in age-related reference values. Our results were not significantly different from those of the Korean population in the past, except for a small decline in the young population. There seemed to be a clear inter-ethnic difference in CRF. We could also identify signs of small change in CRF in younger age groups. Therefore, CRF should be assessed according to ethnic or national standards, and it will be necessary to establish a reference for each nation or ethnicity with periodic updates.

1 January 2019 in Journal of Lipid and Atherosclerosis
Verified
Journal Article
Open access
Jah Yeon ChoiJah Yeon Choi
Jah Yeon Choi
JNJin Oh Na
Jin Oh Na
Dyslipidemia, highly elevated, low-density lipoprotein (LDL) cholesterol, is a major cardiovascular risk factor. Statins have been proven to effectively reduce the risk of atherosclerotic cardiovascular disease (ASCVD) and are recommended as a first-line therapy for the primary and secondary prevention of ASCVD. However, statins may not be sufficient in decreasing LDL cholesterol levels and pose a significant on-treatment residual risk of major cardiovascular events (i.e., residual cholesterol risk) according to meta-analyses of statin trials. Current guidelines for cholesterol management to achieve additional LDL cholesterol reduction and reduce ASCVD risk recommend two hyperlipidemic agents besides statins. Use of ezetimibe, a cholesterol absorption inhibitor, leads to additional LCL cholesterol reduction and decreased ASCVD risk, when added to statin therapy, without raising significant safety concerns. Furthermore, in combination with a mild-to-moderate statin intensity, ezetimibe is used in situations of statin-associated adverse effects such as myalgia and the combination therapy is relatively safer. Monoclonal antibody of proprotein convertase subtilisin/kexin type 9 (PCSK9), alirocumab, and evolocumab, have been approved to lower LDL cholesterol level. While there are drawbacks to the use of PCSK9 inhibitors, including high cost and adverse events such as injection site reaction, they significantly decreased serum LDL cholesterol levels and thereby ASCVD risks when added to maximally tolerated statin therapy.